 |
Tuberculosis-associated immune reconstitution
disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa.
Stephen D. Lawn, Landon Myer, Linda-Gail Bekker, Robin Wood
Source: AIDS 2007, 21:335–341
Objective:
To determine the burden and impact of immune reconstitution disease (IRD) associated with tuberculosis (TB) among patients initiating antiretroviral treatment
(ART) in sub-Saharan Africa.
Read Abstract | View
Full
Text: PDF (130KB)
|
When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study.
Badri M, Cleary S, Maartens G, Pitt J, Bekker LG, Orrell C, Wood R
Source: Antivir Ther, 11(1): 63-72 2006
Abstract Background:
Large-scale programmes increasing access to highly active antiretroviral therapy (HAART) are being implemented in sub-Saharan Africa. However, cost-effectiveness of initiating treatment at different CD4 count thresholds has not been explored in resource-poor
settings
Read Abstract
|
Short-term risk of AIDS or death in people infected with HIV-1 before antiretroviral therapy in South Africa: a longitudinal
study.
Badri M, Lawn SD, Wood R.
Scource: The Lancet. 2006 Oct 7;368(9543):1254-9
Abstract
Background:
In sub-Saharan Africa, data for short-term risk of AIDS or death, which might inform decisions about when to start antiretroviral therapy (ART), are scarce. Our aim was to investigate these risks in patients who had no access to ART or who were given zidovudine alone.
Read Abstract
|
Rapid scale-up of a community-based HIV treatment service: programme performance over 3 consecutive years in Guguletu, South Africa.
Bekker LG , Myer L , Orrell C , Lawn S , Wood R
Source: S Afr Med J, 96(4): 315-20 2006
Abstract Background:
Despite rapid expansion of antiretroviral therapy (ART) in sub-Saharan Africa there are few longitudinal data describing programme performance during rapid
scale-up.
Read Abstract | View Full
Text: PDF (332KB)
|
Determinants of Mortality and
non-death losses from an Antiretroviral Treatment Service in South Africa: Implications for Program Evaluation.
Stephen D. Lawn, Landon Myer, Guy Harling, Catherine Orrell, Linda-Gail Bekker,
Robin Wood
Source: Clinical Infectious Diseases, volume 43 (2006), pages 770–776
Abstract Background:
The scale-up of antiretroviral treatment (ART) services in resource-limited settings requires a programmatic model to deliver care to large numbers of people. Understanding the determinants of key outcome
measures including death and non- death losses would assist in program evaluation and development.
Read Abstract
|
Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis
control.
Lawn SD, Myer L, Bekker LG, Wood R.
Source: AIDS. 2006 Aug 1;20(12):1605-12.
Objectives:
To determine burden and risk factors for tuberculosis (TB) in an antiretroviral treatment (ART) programme and its impact on ART
outcomes.
Read Abstract
|
Undiagnosed Tuberculosis in a Community with High HIV Prevalence: Implications for Tuberculosis
Control.
Wood R, Middelkoop K, Myer L, Grant AD, Whitelaw A, Lawn SD, Kaplan G, Huebner R, McIntyre J, Bekker LG.
Source: Am J Respir Crit Care Med. 2007 Jan 1;175(1):87-93.
Abstract Background:
Although failure of tuberculosis (TB) control in sub-Saharan Africa is attributed to the HIV epidemic, it is unclear why the directly observed therapy short-course (DOTS) strategy is insufficient in this setting. We conducted a cross-sectional survey of pulmonary TB (PTB) and HIV infection in a community of 13,000 with high HIV prevalence and high TB notification rate and a well-functioning DOTS TB control program.
Read Abstract
|
Mental health and sexual risk behaviours in a South African township: A community-based cross-sectional study.
J. Smit, L. Myer, K. Middelkoop, S. Seedat, R. Wood, L.-G. Bekker,
D.J. Stein
Source: Public Health, Volume 120, Issue 6 , June 2006, Pages 534-542
Objectives
Despite the high prevalence of both mental illness and human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) in developing countries, there are few data on the association between different forms of mental illness and sexual risk behaviours in resource-poor settings. The objective of this study was to examine the association between mental illness and HIV risk behaviours in a South African township.
Read Abstract
|
The Maturing Immune System: Implications for Development and Testing HIV-1 Vaccines for Children and Adolescents.
Heather B. Jaspan; Stephen D. Lawn; Jeffrey T. Safrit; Linda-Gail Bekker
Source: AIDS 03/03/2006
Introduction:
Development of an effective HIV-1 vaccine would greatly advance prospects for control of the AIDS epidemic. To date, development of vaccine candidates has been of limited success, demanding innovative approaches to vaccine
technology. Inactivated and live attenuated vaccine technology, so successful in vaccinology of other pathogens, is considered too risky for HIV
infection. Subunit vaccines have been ineffective, failing to elicit neutralizing antibody
responses. Therefore sterilizing immunity, which is thought to be critical for prevention of infection, seems an unlikely
prospect. Current promising DNA and vector-based vaccine candidates in or about to enter phase
1 trials are designed to induce cellular immune responses that prevent persistent infection or disease development rather than acquisition of infection. Even if these problems are overcome, the clinical testing of a successful vaccine is estimated to take at least 10 years with the best collaborative global
efforts.
Read
Full Text Online
|
CD4 cell count recovery among HIV-infected patients with very advanced immunodeficiency commencing antiretroviral treatment in sub-Saharan Africa.
Stephen D Lawn, Landon Myer, Linda-Gail Bekker, Robin Wood
Scource: BMC Infect Dis. 2006; 6: 59.
Abstract Background:
Patients accessing antiretroviral treatment (ART) programmes in sub-Saharan Africa frequently have very advanced immunodeficiency. Previous data suggest that such patients may have diminished capacity for CD4 cell count
recovery.
Read Abstract | Download Full
Text: PDF (296KB)
|
|
|
|
